AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33355421 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 75
Study 33355421 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intake of folates, vitamin D, vitamin E, magnesium, zinc, and copper
Number of subjects: 75
Study 33355421 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended sleep duration
Number of subjects: 75
Study 33355421 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase of BMI percentile
Number of subjects: 75
Study 34936615 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted lymphaticovenous anastomosis
Number of subjects: 20
Study 34936615 — intervention group
Group type: COMPARATOR
Intervention: Manual lymphaticovenous anastomosis
Number of subjects: 20
Study 32470753 — intervention group
Group type: EXPERIMENTAL
Intervention: Active suicidal intent (wanted to die)
Number of subjects: 274
Study 32470753 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive suicidal intent (didn't care about the risks)
Number of subjects: 274
Study 32470753 — intervention group
Group type: COMPARATOR
Intervention: Active/passive intent (vs. no intent)
Number of subjects: 274
Study 32470753 — intervention group
Group type: COMPARATOR
Intervention: Use of ≥5 substances (vs. 1 substance)
Number of subjects: 274
Study 32470753 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine or crack use during last overdose
Number of subjects: 274
Study 36494654 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized PEEP
Number of subjects: 106
Study 36494654 — intervention group
Group type: COMPARATOR
Intervention: Lung-protective ventilation with PEEP of 5 cm H2O
Number of subjects: 106
Study 32616883 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week exercise intervention
Number of subjects: 46
Study 32616883 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 46
Study 34423370 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 4401
Study 34423370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4401
Study 32963103 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (72 IU)
Number of subjects: 28
Study 32963103 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (72 IU) with instructed mimicry
Number of subjects: 28
Study 32963103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 37137551 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise with painful injection (hypertonic saline, 5.8%)
Number of subjects: 34
Study 37137551 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise with non-painful injection (isotonic saline, 0.9%)
Number of subjects: 34
Study 37137551 — intervention group
Group type: COMPARATOR
Intervention: Painful injection (hypertonic saline, 5.8%)
Number of subjects: 34
Study 37137551 — intervention group
Group type: COMPARATOR
Intervention: Non-painful injection (isotonic saline, 0.9%)
Number of subjects: 34
Study 33676870 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib plus endocrine therapy
Number of subjects: 2
Study 33676870 — intervention group
Group type: COMPARATOR
Intervention: Endocrine therapy alone
Number of subjects: 2
Study 32998747 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-week (5 fractions) regimen of radiotherapy (26 Gy/5 fractions/1 week)
Number of subjects: 2100
Study 32998747 — intervention group
Group type: COMPARATOR
Intervention: Standard 3-week (15 fractions) schedule of radiotherapy (40 Gy/15 fractions/3 weeks)
Number of subjects: 2100
Study 37552627 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person SMART training (video teleconference or face-to-face)
Number of subjects: 56
Study 37552627 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based SMART training
Number of subjects: 56
Study 34417343 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous lidocaine infusion
Number of subjects: 120
Study 34417343 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided unilateral, single-injection TAP block
Number of subjects: 120
Study 32656713 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory loss
Number of subjects: 100
Study 32656713 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinonasal symptoms
Number of subjects: 100
Study 32656713 — intervention group
Group type: EXPERIMENTAL
Intervention: Taste impairment
Number of subjects: 100
Study 32656713 — intervention group
Group type: EXPERIMENTAL
Intervention: Age relation to sinonasal symptoms
Number of subjects: 100
Study 32656713 — intervention group
Group type: EXPERIMENTAL
Intervention: Relation between olfactory loss and sinonasal symptoms
Number of subjects: 100
Study 36113201 — intervention group
Group type: EXPERIMENTAL
Intervention: PPT-based training (8 sessions)
Number of subjects: 64
Study 36113201 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control group)
Number of subjects: 64
Study 34648905 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee beverage A (400 mL/day containing 787 mg of chlorogenic acids)
Number of subjects: 74
Study 34648905 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee beverage B (400 mL/day containing 407 mg of chlorogenic acids)
Number of subjects: 74
Study 34648905 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified, assumed no coffee consumption)
Number of subjects: 74
Study 32619388 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologics
Number of subjects: 156
Study 32619388 — intervention group
Group type: COMPARATOR
Intervention: Non-biologics
Number of subjects: 156
Study 32619388 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 156
Study 33712253 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 µg.kg-1 clonidine intravenously
Number of subjects: 62
Study 33712253 — intervention group
Group type: COMPARATOR
Intervention: Control group (no clonidine)
Number of subjects: 62
Study 33712253 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 62
Study 34140087 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal binder worn during the daytime for 14 days after surgery
Number of subjects: 40
Study 34140087 — intervention group
Group type: COMPARATOR
Intervention: No abdominal binder
Number of subjects: 40
Study 34140087 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal binder
Number of subjects: 40
Study 32890444 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue (MB/PDT group)
Number of subjects: 20
Study 32890444 — intervention group
Group type: COMPARATOR
Intervention: Methyl aminolevulinate (MAL/PDT group)
Number of subjects: 20
Study 36181992 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT)
Number of subjects: 24
Study 33725323 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (2.5 mg twice daily) plus Aspirin (100 mg once daily)
Number of subjects: 0
Study 33725323 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 0
Study 32891268 — intervention group
Group type: EXPERIMENTAL
Intervention: Auriculotherapy
Number of subjects: 128
Study 32891268 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 128
Study 35086621 — intervention group
Group type: EXPERIMENTAL
Intervention: 4R (rifampicin for 4 months)
Number of subjects: 1017
Study 35086621 — intervention group
Group type: COMPARATOR
Intervention: 9H (isoniazid for 9 months)
Number of subjects: 1017
Study 34272849 — intervention group
Group type: EXPERIMENTAL
Intervention: lonapegsomatropin 0.24 mg hGH/kg/week
Number of subjects: 161
Study 34272849 — intervention group
Group type: COMPARATOR
Intervention: daily somatropin (equivalent weekly dose delivered daily)
Number of subjects: 161
Study 32561603 — intervention group
Group type: EXPERIMENTAL
Intervention: MSCT monotherapy
Number of subjects: 63
Study 32561603 — intervention group
Group type: EXPERIMENTAL
Intervention: MSCT plus recombinant human IFN-γ treatment
Number of subjects: 63
Study 35242203 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic monitoring of lipid metabolism indexes and regulation of blood lipids on top of routine hypoglycemic treatment (Group B)
Number of subjects: 192
Study 35242203 — intervention group
Group type: COMPARATOR
Intervention: Routine hypoglycemic treatment (Control Group)
Number of subjects: 192
Study 35242203 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum TG level
Number of subjects: 192
Study 35242203 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum TC level
Number of subjects: 192
Study 35242203 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum LDL-C level
Number of subjects: 192
Study 35242203 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum HDL-C level
Number of subjects: 192
Study 35242203 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined detection of lipid metabolism indexes (TC, TG, HDL-C, LDL-C)
Number of subjects: 192
Study 32246779 — intervention group
Group type: EXPERIMENTAL
Intervention: EAT-10 questionnaire
Number of subjects: 57
Study 32246779 — intervention group
Group type: EXPERIMENTAL
Intervention: EAT-10 score cutoff point
Number of subjects: 57
Study 32003816 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention (weekly for 4 weeks, every 2 weeks for 4 weeks, and monthly thereafter, provided relapse prevention therapy and buprenorphine)
Number of subjects: 98
Study 32003816 — intervention group
Group type: COMPARATOR
Intervention: In-person intervention (weekly for 4 weeks, every 2 weeks for 4 weeks, and monthly thereafter, provided relapse prevention therapy and buprenorphine)
Number of subjects: 98
Study 32003816 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention
Number of subjects: 98
Study 32003816 — intervention group
Group type: COMPARATOR
Intervention: In-person intervention
Number of subjects: 98
Study 32753555 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (ET)
Number of subjects: 128
Study 35660987 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysphagia Standard Assessment (DSA®) test with different volumes and viscosities
Number of subjects: 72
Study 32981755 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN)
Number of subjects: 690
Study 33934076 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg Q4W
Number of subjects: 1120
Study 33934076 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg Q8W
Number of subjects: 1120
Study 33934076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1120
Study 32041720 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (Eylea) given via loading dose (three injections) followed by treat and extend protocol over 12 months
Number of subjects: 30
Study 34014028 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg naltrexone
Number of subjects: 67
Study 34014028 — intervention group
Group type: COMPARATOR
Intervention: 10 mg amitriptyline
Number of subjects: 67
Study 34014028 — intervention group
Group type: EXPERIMENTAL
Intervention: naltrexone
Number of subjects: 67
Study 34014028 — intervention group
Group type: COMPARATOR
Intervention: amitriptyline
Number of subjects: 67
Study 32647469 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma (PRP)
Number of subjects: 26
Study 32647469 — intervention group
Group type: COMPARATOR
Intervention: Platelet Rich Fibrin (PRF)
Number of subjects: 26
Study 34654525 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly participatory art-based activities at the Montreal Museum of Fine Arts over a 3-month period
Number of subjects: 165
Study 34654525 — intervention group
Group type: COMPARATOR
Intervention: Control group (no participation in art-based activities)
Number of subjects: 165
Study 33835035 — intervention group
Group type: COMPARATOR
Intervention: Revised CDS influenza alert
Number of subjects: 0
Study 33835035 — intervention group
Group type: COMPARATOR
Intervention: Three versions of text supporting tobacco cessation alerts (financial, quality, regulatory) with three supporting images
Number of subjects: 0
Study 33218513 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthotic-garment worn throughout the day with maximal cane-use reduction (Phase B)
Number of subjects: 4
Study 33218513 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant-determined follow-up (Phase C)
Number of subjects: 4
Study 33218513 — intervention group
Group type: COMPARATOR
Intervention: Cane-walking 'as usual' (Phase A)
Number of subjects: 4
Study 32998597 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing intervention
Number of subjects: 90
Study 32998597 — intervention group
Group type: COMPARATOR
Intervention: Non-emotional writing intervention (Control)
Number of subjects: 90
Study 34146843 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated person-centred palliative care delivered by multidisciplinary palliative care teams working with general practitioners and community nurses.
Number of subjects: 50
Study 34146843 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 50
Study 32864921 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard nursing guidelines
Number of subjects: 44
Study 32864921 — intervention group
Group type: COMPARATOR
Intervention: Routine institutional orientation
Number of subjects: 44
Study 34896444 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored educational materials
Number of subjects: 219
Study 34896444 — intervention group
Group type: COMPARATOR
Intervention: Existing national screening guidelines
Number of subjects: 219
Study 33450079 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO-7684 (250 mg daily for 14 days)
Number of subjects: 100
Study 33450079 — intervention group
Group type: COMPARATOR
Intervention: ONO-7684 (1-300 mg single doses)
Number of subjects: 100
Study 33450079 — intervention group
Group type: COMPARATOR
Intervention: ONO-7684 (single and multiple doses)
Number of subjects: 100
Study 33450079 — intervention group
Group type: COMPARATOR
Intervention: ONO-7684 (single doses)
Number of subjects: 100
Study 33450079 — intervention group
Group type: COMPARATOR
Intervention: ONO-7684 (multiple doses)
Number of subjects: 100
Study 32532346 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-h single-session skills-based pain management class
Number of subjects: 136
Study 32532346 — intervention group
Group type: COMPARATOR
Intervention: 2-h health education active control group
Number of subjects: 136
Study 33618060 — intervention group
Group type: EXPERIMENTAL
Intervention: ROR plus video and text messages (enhanced ROR)
Number of subjects: 160
Study 33618060 — intervention group
Group type: COMPARATOR
Intervention: Standard Reach Out and Read (ROR)
Number of subjects: 160
Study 33059633 — intervention group
Group type: COMPARATOR
Intervention: Conventional care (control group)
Number of subjects: 3922
Study 33059633 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient self‐monitoring group
Number of subjects: 3922
Study 33059633 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwife‐assisted RM group
Number of subjects: 3922
Study 36231362 — intervention group
Group type: EXPERIMENTAL
Intervention: Intuitive eating intervention (5 weeks facilitated by Registered Dietitians)
Number of subjects: 14
Study 36231362 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (no intervention)
Number of subjects: 14
Study 34268944 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy
Number of subjects: 44
Study 34268944 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab alone
Number of subjects: 44
Study 34846023 — intervention group
Group type: EXPERIMENTAL
Intervention: DBC treatment with modern rehabilitation equipment
Number of subjects: 196
Study 34846023 — intervention group
Group type: COMPARATOR
Intervention: Traditional form of therapeutic exercise
Number of subjects: 196
Study 36006997 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing reeducation (BR)
Number of subjects: 68
Study 36006997 — intervention group
Group type: COMPARATOR
Intervention: Routine physical therapy (RPT)
Number of subjects: 68
Study 34250935 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary AGEs reduction intervention (in addition to standard of care guidelines)
Number of subjects: 75
Study 34250935 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) guidelines for good glycemic control
Number of subjects: 75
Study 34250935 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary AGEs reduction intervention
Number of subjects: 75
Study 34250935 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) guidelines
Number of subjects: 75
Study 36130917 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-supported, web-based intervention (n = 50)
Number of subjects: 103
Study 36130917 — intervention group
Group type: COMPARATOR
Intervention: Standard care control (n = 53)
Number of subjects: 103
Study 34177914 — intervention group
Group type: EXPERIMENTAL
Intervention: AERAS‐402 (3 x 10^10 viral particles)
Number of subjects: 12
Study 34177914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 33107334 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic sacral colpopexy using autologous fascia lata
Number of subjects: 64
Study 33107334 — intervention group
Group type: COMPARATOR
Intervention: Robotic sacral colpopexy using synthetic mesh
Number of subjects: 64
Study 35969933 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education bundle intervention
Number of subjects: 16865
Study 35969933 — intervention group
Group type: COMPARATOR
Intervention: Control group (pre-intervention)
Number of subjects: 16865
Study 33752222 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength-dominated exercise program (10 weeks, 3 times per week, 30 minutes per session)
Number of subjects: 54
Study 33752222 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 54
Study 33685871 — intervention group
Group type: EXPERIMENTAL
Intervention: App-based treatment (URinControl)
Number of subjects: 262
Study 33685871 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 262
Study 32041657 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX 25 mg (oral or subcutaneous) once weekly plus LEF 20 mg daily
Number of subjects: 78
Study 32041657 — intervention group
Group type: COMPARATOR
Intervention: Placebo instead of LEF daily
Number of subjects: 78
Study 36103724 — intervention group
Group type: COMPARATOR
Intervention: Simulated altitude at 0 m (sea level, SL)
Number of subjects: 24
Study 36103724 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated altitude at 1111 m (MILD)
Number of subjects: 24
Study 36103724 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated altitude at 2222 m (MOD)
Number of subjects: 24
Study 33787632 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) for 2 weeks
Number of subjects: 42
Study 33787632 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IMT)
Number of subjects: 42
Study 33256863 — intervention group
Group type: EXPERIMENTAL
Intervention: Camels aged 6-10 years
Number of subjects: 493
Study 33256863 — intervention group
Group type: EXPERIMENTAL
Intervention: Herds with 25 or more camels
Number of subjects: 493
Study 33256863 — intervention group
Group type: EXPERIMENTAL
Intervention: Camels from Gabra community
Number of subjects: 493
Study 33256863 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall MERS-CoV IgG seropositivity
Number of subjects: 493
Study 36249235 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Breathing Technique (SBT)
Number of subjects: 3
Study 36249235 — intervention group
Group type: EXPERIMENTAL
Intervention: Long Duration Breathing Technique (LBDT)
Number of subjects: 3
Study 36249235 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogic breathing
Number of subjects: 3
Study 36249235 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3
Study 32004081 — intervention group
Group type: EXPERIMENTAL
Intervention: MAP72 (mean arterial pressure target of 72 mm Hg)
Number of subjects: 50
Study 32004081 — intervention group
Group type: COMPARATOR
Intervention: MAP65 (mean arterial pressure target of 65 mm Hg)
Number of subjects: 50
Study 35780811 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical management with mifepristone and misoprostol
Number of subjects: 1000000
Study 35780811 — intervention group
Group type: COMPARATOR
Intervention: Office uterine aspiration
Number of subjects: 1000000
Study 34043158 — intervention group
Group type: COMPARATOR
Intervention: Transarterial chemoembolization (cTACE) using Lipiodol only (group 1)
Number of subjects: 61
Study 34043158 — intervention group
Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolization (cTACE) using Lipiodol combined with degradable starch microspheres (DSM) (group 2)
Number of subjects: 61
Study 34043158 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival for cTACE with Lipiodol plus DSM
Number of subjects: 61
Study 34043158 — intervention group
Group type: COMPARATOR
Intervention: Overall survival for cTACE with Lipiodol only
Number of subjects: 61
Study 32030734 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed fluid therapy (n = 142)
Number of subjects: 283
Study 32030734 — intervention group
Group type: COMPARATOR
Intervention: Standard fluid therapy (n = 141)
Number of subjects: 283
Study 34585675 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride
Number of subjects: 0
Study 34585675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33781134 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior reconstruction of pubourethralis with Rocco stitch
Number of subjects: 206
Study 33781134 — intervention group
Group type: COMPARATOR
Intervention: Rocco stitch (control group)
Number of subjects: 206
Study 32661605 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight and obese children
Number of subjects: 0
Study 32661605 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with both overweight and hypertension
Number of subjects: 0
Study 32661605 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral and central SBP, body mass index (BMI), and hemodynamic parameters
Number of subjects: 0
Study 32661605 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral and central SBP and cardiac index
Number of subjects: 0
Study 32661605 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower and highest 24‐h PWV quartile groups
Number of subjects: 0
Study 32473624 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 0
Study 32473624 — intervention group
Group type: EXPERIMENTAL
Intervention: Romiplostim
Number of subjects: 0